Skip to main content
SpringerLink
Log in

Is left ventricular dysfunction reversed after treatment of active acromegaly?

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

It has been suggested that control of GH and IGF excess can arrest the progression of cardiovascular abnormalities and normalize cardiac performance. The aim of the present study was to investigate the reversibility of acromegalic cardiomyopathy in patients with active and inactive disease and to evaluate the effect of the inactivity of the disease on left ventricular (LV) diastolic dysfunction, irrespective of the applied treatment. The patient population consisted of 55 patients who were studied in the active and/or inactive phase. A complete M-mode, two-dimensional and color-flow Doppler echocardiographic examination was performed. LV mass index and posterior wall index were significantly lower in patients with inactive acromegaly compared to those with active disease (P < 0.03 respectively). Diastolic dysfunction was improved in patients with inactive compared to those with active disease (E/A ratio P < 0.009). IGF was positively correlated with LV mass index (r = 0.28, P < 0.02). Multivariate linear regression analysis showed that in active patients the E/A ratio was independently related to age (β = −0.674, P < 0.001) and GH (β = 0.282, P < 0.03), whereas in inactive patients none of the parameters were related significantly with the E/A ratio. In a subgroup of 15 patients who were studied in both the active and inactive phase of the disease, the reduction in GH levels was correlated positively with the reduction in LV mass index (r = 0.89, P < 0.0001) and negatively with the improvement in E/A ratio (r = −0.74, P < 0.001). In conclusion, the results of the present study indicate an improvement of left ventricular diastolic function and a significant improvement of cardiac hypertrophy in patients with inactive acromegaly and normal systolic cardiac function compared to those with active disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Clayton RN (2003) Cardiovascular function on acromegaly. Endocr Rev 24:272–277

    Article  CAS  PubMed  Google Scholar 

  2. Delafontaine P (1995) Insulin-like growth factor 1 and its binding proteins in the cardiovascular system. Cardiovasc Res 30:825–834

    CAS  PubMed  Google Scholar 

  3. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58:169–176

    Article  CAS  Google Scholar 

  4. Thuesen I, Christensen SE, Weeke J, Orskov H, Hemingsen P (1989) The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol 30:619–625

    Article  CAS  Google Scholar 

  5. Merola B, Citadini A, Colao A, Ferone D, Fazio S, Sabatini D, Biondi B, Saccá L, Lombardi G (1993) Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 77:790–793

    Article  CAS  PubMed  Google Scholar 

  6. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G (1999) Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84:527–532

    Article  CAS  PubMed  Google Scholar 

  7. Sahn DJ, De Maria A, Kisslo J (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083

    CAS  PubMed  Google Scholar 

  8. Zakopoulos NA, Tsivgoulis G, Barlas G, Spengos K, Manios E, Ikonomidis I, Toumanidis S, Dolianitis K, Vemmos K, Vassilopoulos D, Moulopoulos SD (2006) Impact of the time rate of blood pressure variation on left ventricular mass. J Hypertens 24:2071–2077

    Article  CAS  PubMed  Google Scholar 

  9. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458

    Article  CAS  PubMed  Google Scholar 

  10. Colao A (2008) The GH-IgF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 69:347–358

    Article  CAS  Google Scholar 

  11. Minniti G, Moroni C, Jaffrain-Rea ML et al (2001) Marked improvement of cardiovascular function after successful transphenoidal surgery in acromegalic patients. Clin Endocrinol 55:307–313

    Article  CAS  Google Scholar 

  12. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metabol 85:3132–3140

    Article  CAS  Google Scholar 

  13. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J (2010) Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13:18–28

    Article  CAS  PubMed  Google Scholar 

  14. De Marinis L, Bianchi A, Maziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A (2008) The long-term cardiovascular outcome of different GH-lowerng treatment in acromegaly. Pituitary 11:13–20

    Article  CAS  PubMed  Google Scholar 

  15. Colao A, Cuocolo A, Marzullo P, Nikolai E (1999) Effects of 1-year treatment with Octreotide on cardiac performance in patients with acromegaly. J Clin Endocrin Metab 84:17–23

    Article  CAS  Google Scholar 

  16. Colao LG, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S (2002) Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinl Invest 25:971–976

    Google Scholar 

  17. Pereira JL, Rodriguez-Puraw MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, Pumar A, Astorga R (1991) Acromegalic cardiomyopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 14:17–23

    CAS  PubMed  Google Scholar 

  18. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D’Errico A, Kourides I, Burman P, Lombardi G, Colao A (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 92:476–482

    Article  CAS  PubMed  Google Scholar 

  19. van Thiel SW, Bax JJ, Biermasz NR, Holman ER, Poldermans D, Roelfsema F, Lamb HJ, van der Wall EE, Smit JW, Romijn JA, Pereira AM (2005) Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol 153:231–238

    Article  CAS  PubMed  Google Scholar 

  20. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly, epidemiology, pathogenesis and management. Endocrin Rev 25:105–152

    Article  Google Scholar 

  21. Leaes C, Kramer C (2009) Diastolic function study with conventional and pulsed tissue doppler echocardiography imaging in acromegalic patients. Echocardiography 26:651–656

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, Medical School, University of Athens, “Alexandra” Hospital, 80 Vas. Sophias Ave.—Lourou Str., 115 28, Athens, Greece

    Savvas T. H. Toumanidis, Maria Eleftheria Evangelopoulos, Ioannis Ilias, Constantinos Pamboucas, Chrysanthi Trikka & Maria Alevizaki

Authors
  1. Savvas T. H. Toumanidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Eleftheria Evangelopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ioannis Ilias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Constantinos Pamboucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chrysanthi Trikka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Alevizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Savvas T. H. Toumanidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toumanidis, S.T.H., Evangelopoulos, M.E., Ilias, I. et al. Is left ventricular dysfunction reversed after treatment of active acromegaly?. Pituitary 14, 75–79 (2011). https://doi.org/10.1007/s11102-010-0263-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-010-0263-2

Keywords

Search

Navigation